Please assess the completion status of the following clinical trial:

Trial Title: Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* ≥ 8 years of age and \< 19 years of age at the time of registration~* Newly diagnosed with cancer~* Chemotherapy naive~* Scheduled to receive moderately or highly emetogenic chemotherapy (non-steroid containing regimen) as an in-patient. (Refer to Appendix IV. In multiple agent regimens, select the agent with the highest emetic potential.)~* Scheduled for placement of IV accesses device(s) for treatment purposes (allowing a dedicated line for continuous infusion of study agent)~* Not pregnant or lactating~EXCLUSION CRITERIA:~* Prior chemotherapy~* Central Nervous System disease~* Stem cell transplant while on-study~* Out-patient chemotherapy~* Steroids are included in their chemotherapy regimen~* Contraindication to the use of dexamethasone (e.g. diabetes)~* Hepatic and/or renal failure~* Allergic to any of the study medications~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Benadryl® Ativan® Decadron® (BAD) Pump (Type: EXPERIMENTAL): Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
- Control Arm Saline (Type: ACTIVE_COMPARATOR): Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).